The pharmaceutical group Pfizer today presented its business figures for 2024 and, despite declining COVID-19 revenues, can report solid growth. Total revenue rose by 7% to $63.6 billion in 2024[1]. The non-COVID business developed particularly pleasingly with operational growth of 12%[1].
Adjusted earnings per share reached $3.11, an increase of 69% compared to the previous year[1]. Growth drivers included, among others, the integration of the acquired cancer specialist Seagen and strong growth for the drug Vyndaqel for the treatment of a rare heart disease[1].
For the current year 2025, Pfizer confirms its forecast and expects revenue between $61.0 billion and $64.0 billion[1]. The company is also making progress on its cost reduction program and aims to achieve savings of around $4.5 billion by the end of 2025[1].
CEO Albert Bourla expressed satisfaction with the business development: "2024 was a year of strong execution and performance for Pfizer, in which we met or exceeded our strategic and financial commitments"[1]. CFO David Denton emphasized the successful commercial execution and progress in cost savings[1].
In the fourth quarter of 2024, Pfizer achieved revenue of $17.8 billion, an operational growth of 21%[1]. The company was able to more than offset declining revenues from COVID-19 products with growth in other areas. Shareholders received dividends totaling $9.5 billion in 2024[1].
Sources:
[1] Q4-2024-PFE-Earnings-Release-Final.pdf https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/21436693/17ad630c-2590-4664-9818-c7dcff07395a/Q4-2024-PFE-Earnings-Release-Final.pdf
